These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 8069713)

  • 1. [Regulation of osteoclastic resorption by prostanoids in vivo].
    Saffar JL; Lasfargues JJ; Leroux P; Guez D
    C R Seances Soc Biol Fil; 1993; 187(5):608-19. PubMed ID: 8069713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of osteoclastic motility by prostaglandins I2, E1, E2 and 6-oxo-E1.
    Chambers TJ; Ali NN
    J Pathol; 1983 Mar; 139(3):383-97. PubMed ID: 6339702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
    Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
    Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of prostaglandin inhibition on the bone activities associated with the spontaneous drift of molar teeth in the rat.
    Lasfargues JJ; Saffar JL
    Anat Rec; 1992 Nov; 234(3):310-6. PubMed ID: 1443660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
    J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro.
    Huang J; Yuan L; Wang X; Zhang TL; Wang K
    Life Sci; 2007 Aug; 81(10):832-40. PubMed ID: 17764702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of bone resorption and osteoclast survival by nitric oxide: possible involvement of NMDA-receptor.
    Mentaverri R; Kamel S; Wattel A; Prouillet C; Sevenet N; Petit JP; Tordjmann T; Brazier M
    J Cell Biochem; 2003 Apr; 88(6):1145-56. PubMed ID: 12647297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minocycline impairment of both osteoid tissue removal and osteoclastic resorption in a synchronized model of remodeling in the rat.
    Klapisz-Wolikow M; Saffar JL
    J Cell Physiol; 1996 May; 167(2):359-68. PubMed ID: 8613479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of osteoclast differentiation and bone resorption by a novel lysophosphatidylcholine derivative, SCOH.
    Kwak HB; Lee SW; Li YJ; Kim YA; Han SY; Jhon GJ; Kim HH; Lee ZH
    Biochem Pharmacol; 2004 Apr; 67(7):1239-48. PubMed ID: 15013839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of prostanoid synthesis depresses alveolar bone resorption but enhances root resorption in the rat.
    Lasfargues JJ; Saffar JL
    Anat Rec; 1993 Dec; 237(4):458-65. PubMed ID: 8311258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of wortmannin analogs on bone in vitro and in vivo.
    Sato M; Bryant HU; Dodge JA; Davis H; Matter WF; Vlahos CJ
    J Pharmacol Exp Ther; 1996 Apr; 277(1):543-50. PubMed ID: 8613966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The majority of osteoclasts require mRNA and protein synthesis for bone resorption in vitro.
    Hall TJ; Schaeublin M; Chambers TJ
    Biochem Biophys Res Commun; 1993 Sep; 195(3):1245-53. PubMed ID: 8216256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-effect and evidence of escape of inhibition after indomethacin treatment in a synchronized model of bone resorption.
    Leroux P; Saffar JL
    Agents Actions; 1993 Mar; 38(3-4):290-4. PubMed ID: 8213357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia is a major stimulator of osteoclast formation and bone resorption.
    Arnett TR; Gibbons DC; Utting JC; Orriss IR; Hoebertz A; Rosendaal M; Meghji S
    J Cell Physiol; 2003 Jul; 196(1):2-8. PubMed ID: 12767036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinoid-induced bone thinning is caused by subperiosteal osteoclast activity in adult rodents.
    Kneissel M; Studer A; Cortesi R; Susa M
    Bone; 2005 Feb; 36(2):202-14. PubMed ID: 15780946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge.
    Kim HH; Kim JH; Kwak HB; Huang H; Han SH; Ha H; Lee SW; Woo ER; Lee ZH
    Biochem Pharmacol; 2004 May; 67(9):1647-56. PubMed ID: 15081864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H1 and H2 histamine receptors modulate osteoclastic resorption by different pathways: evidence obtained by using receptor antagonists in a rat synchronized resorption model.
    Dobigny C; Saffar JL
    J Cell Physiol; 1997 Oct; 173(1):10-8. PubMed ID: 9326444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An osteoclastic protein-tyrosine phosphatase is a potential positive regulator of the c-Src protein-tyrosine kinase activity: a mediator of osteoclast activity.
    Lau KH; Wu LW; Sheng MH; Amoui M; Suhr SM; Baylink DJ
    J Cell Biochem; 2006 Apr; 97(5):940-55. PubMed ID: 16267838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.